Extracorporeal membrane oxygenation (ECMO) is a potentially lifesaving procedure in acute respiratory distress syndrome (ARDS) due to COVID-19. Previous studies have shown a high prevalence of clinically silent cerebral microbleeds in patients with COVID-19. Based on this fact, together with the hemotrauma and the requirement of therapeutic anticoagulation on ECMO support, we hypothesized an increased risk of intracranial hemorrhages (ICHs). We analyzed ICH occurrence rate, circumstances and clinical outcome in patients that received ECMO support due to COVID-19-induced ARDS in comparison to viral non-COVID-19-induced ARDS intracerebral hemorrhage.

中文翻译：

---

体外膜氧合引起的颅内出血：COVID-19 与其他病毒性急性呼吸窘迫综合征之间的差异。

体外膜肺氧合 (ECMO) 是治疗因 COVID-19 导致的急性呼吸窘迫综合征 (ARDS) 的一种可能挽救生命的手术。先前的研究表明，COVID-19 患者临床无症状脑微出血的患病率很高。基于这一事实，再加上血伤和 ECMO 支持下抗凝治疗的要求，我们假设颅内出血 (ICH) 的风险增加。我们分析了因 COVID-19 诱发的 ARDS 与病毒性非 COVID-19 诱发的 ARDS 脑出血而接受 ECMO 支持的患者的 ICH 发生率、情况和临床结果。